Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Insulin Transdermal Delivery System for Diabetes Treatment Using a Biocompatible Ionic Liquid-Based Microemulsion.

Tytuł:
Insulin Transdermal Delivery System for Diabetes Treatment Using a Biocompatible Ionic Liquid-Based Microemulsion.
Autorzy:
Islam MR; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.; Department of Applied Chemistry and Chemical Engineering, Noakhali Science and Technology University, Noakhali 3814, Bangladesh.
Uddin S; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
Chowdhury MR; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
Wakabayashi R; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.; Advanced Transdermal Drug Delivery System Centre, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
Moniruzzaman M; Department of Chemical Engineering, Universiti Teknologi PETRONAS, 32610 Seri Iskandar, Perak, Malaysia.
Goto M; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.; Advanced Transdermal Drug Delivery System Centre, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.; Division of Biotechnology, Centre for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
Źródło:
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2021 Sep 15; Vol. 13 (36), pp. 42461-42472. Date of Electronic Publication: 2021 Aug 30.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Washington, D.C. : American Chemical Society
MeSH Terms:
Diabetes Mellitus, Experimental/*drug therapy
Drug Carriers/*chemistry
Emulsions/*chemistry
Insulin/*administration & dosage
Insulin/*therapeutic use
Ionic Liquids/*chemistry
Administration, Cutaneous ; Animals ; Choline/chemistry ; Fatty Acids/chemistry ; Female ; Insulin/chemistry ; Insulin/pharmacokinetics ; Mice, Inbred BALB C ; Permeability ; Skin/metabolism ; Mice
Contributed Indexing:
Keywords: biocompatibility; blood glucose; insulin; microemulsions; pharmacokinetics; surface-active ionic liquids; transdermal delivery systems
Substance Nomenclature:
0 (Drug Carriers)
0 (Emulsions)
0 (Fatty Acids)
0 (Insulin)
0 (Ionic Liquids)
N91BDP6H0X (Choline)
Entry Date(s):
Date Created: 20210830 Date Completed: 20220120 Latest Revision: 20240226
Update Code:
20240226
DOI:
10.1021/acsami.1c11533
PMID:
34460218
Czasopismo naukowe
Since injection administration for diabetes is invasive, it is important to develop an effective transdermal method for insulin. However, transdermal delivery remains challenging owing to the strong barrier function of the stratum corneum (SC) of the skin. Here, we developed ionic liquid (IL)-in-oil microemulsion formulations (MEFs) for transdermal insulin delivery using choline-fatty acids ([Chl][FAs])-comprising three different FAs (C18:0, C18:1, and C18:2)-as biocompatible surface-active ILs (SAILs). The MEFs were successfully developed using [Chl][FAs] as surfactants, sorbitan monolaurate (Span-20) as a cosurfactant, choline propionate IL as an internal polar phase, and isopropyl myristate as a continuous oil phase. Ternary phase behavior, dynamic light scattering, and transmission electron microscopy studies revealed that MEFs were thermodynamically stable with nanoparticle size. The MEFs significantly enhanced the transdermal permeation of insulin via the intercellular route by compromising the tight lamellar structure of SC lipids through a fluidity-enhancing mechanism. In vivo transdermal administration of low insulin doses (50 IU/kg) to diabetic mice showed that MEFs reduced blood glucose levels (BGLs) significantly compared with a commercial surfactant-based formulation by increasing the bioavailability of insulin in the systemic circulation and sustained the insulin level for a much longer period (half-life > 24 h) than subcutaneous injection (half-life 1.32 h). When [Chl][C18:2] SAIL-based MEF was transdermally administered, it reduced the BGL by 56% of its initial value. The MEFs were biocompatible and nontoxic (cell viability > 90%). They remained stable at room temperature for 3 months and their biological activity was retained for 4 months at 4 °C. We believe SAIL-based MEFs will alter current approaches to insulin therapy and may be a potential transdermal nanocarrier for protein and peptide delivery.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies